Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar 1;89(4):843-51.
doi: 10.1093/cvr/cvq359. Epub 2010 Nov 13.

Targeting atrioventricular differences in ion channel properties for terminating acute atrial fibrillation in pigs

Affiliations

Targeting atrioventricular differences in ion channel properties for terminating acute atrial fibrillation in pigs

Sandeep V Pandit et al. Cardiovasc Res. .

Erratum in

  • Cardiovasc Res. 2011 Nov 1;92(2):358

Abstract

Aims: The goal was to terminate atrial fibrillation (AF) by targeting atrioventricular differences in ionic properties.

Methods and results: Optical mapping was used to record electrical activity during carbachol (0.25-0.5 μM)-induced AF in pig hearts. The atrial-specific current, I(Kur), was blocked with 100 μM 4-aminopyridine (4-AP) or with 0.5 μM DPO-1. Hearts in AF and ventricular fibrillation (VF) were also subjected to increasing levels of extracellular K(+) ([K(+)](o): 6-12 mM), compared with controls (4 mM). We hypothesized that due to the more negative steady-state half inactivation voltage for the atrial Na(+) current, I(Na), compared with the ventricle, AF would terminate before VF in hyperkalaemia. Mathematical models were used to interpret experimental findings. The I(Kur) block did not terminate AF in a majority of experiments (6/9 with 4-AP and 3/4 with DPO-1). AF terminated in mild hyperkalaemia ([K(+)](o) ≤ 10.0 mM; N = 8). In contrast, only two of five VF episodes terminated at the maximum ([K(+)](o): 12 mM [K(+)](o)). The I(Kur) block did not terminate a simulated rotor in cholinergic AF because its contribution to repolarization was dwarfed by the large magnitude of the acetylcholine-activated K(+) current (I(K,ACh)). Simulations showed that the lower availability of the atrial Na(+) current at depolarized potentials, and a smaller atrial tissue size compared with the ventricle, could partly explain the earlier termination of AF compared with VF during hyperkalaemia.

Conclusion: I(Kur) is an ineffective anti-arrhythmic drug target in cholinergic AF. Manipulating Na(+) current 'availability' might represent a viable anti-arrhythmic strategy in AF.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Experiments in acute atrial fibrillation and in the presence of IKur blockade. (A) Representative dominant frequency maps and single-pixel recordings during acute atrial fibrillation in the left atrium and the right atrium. (B) Plot of the maximum dominant frequency (DFmax) in acute atrial fibrillation experiments in pig hearts vs. time. Time before the introduction of the drug to selectively block IKur (100 μM 4-AP) is assigned negative values.
Figure 2
Figure 2
Experiments in acute atrial fibrillation and ventricular fibrillation and in the presence of IKur blockade (via DPO-1). (A) Representative pig optical atrial action potential in control (solid) and in the presence of 0.5 μM DPO-1 (dashed) at 300 ms pacing. (B) Representative pig optical ventricular action potential in control (solid) and in the presence of 0.5 μM DPO-1 (dashed) at 300 ms pacing. (C) Average atrial action potential durations at 50% (APD50) and 75% (APD75) repolarization in control and in the presence of 0.5, 1.0, and 5.0 μM DPO-1. (D) Average ventricular action potential durations at 50% (APD50) and 75% (APD75) repolarization in control and in the presence of 0.5 and 1.0 μM DPO-1. (E) Plot of DFmax in acute atrial fibrillation experiments in control and in the presence of 0.5 μM DPO-1. (F) Plot of DFmax during ventricular fibrillation in control and in the presence of 0.5 μM DPO-1. (G) Plot of DFmax in acute atrial fibrillation experiments in control and in the presence of 1.0 and 5.0 μM DPO-1. (H) Plot of DFmax during ventricular fibrillation in control and in the presence of 1.0 and 5.0 μM DPO-1.
Figure 3
Figure 3
Experiments in acute atrial and ventricular fibrillation simultaneously during hyperkalaemia (6–12 mM [K+]o). (A) Representative plots of the dominant frequency maps in acute atrial (in the left atrium) and ventricular fibrillation (in the left ventricle) in the same heart that was perfused at different concentrations of [K+]o at 4, 6, 8, 10, and 12 mM, for 10 min at each concentration. DFmax of atrial fibrillation changed substantially during perfusion of 8 mM [K+]o; hence, three maps at the initial, middle, and final stages of the 10 min perfusion period are shown. Atrial fibrillation converted to atrial tachycardia (ATach) in the final stages and subsequently terminated during transition from 8 to 10 mM [K+]o. In this experiment, ventricular fibrillation did not terminate even at 12 mM [K+]o. (B) Comparison of average DFmax values during atrial and ventricular fibrillation at different concentrations of [K+]o.
Figure 4
Figure 4
New numerical formulation of IKur. (A) Plots of model time constants for the fast and slow time constants of the inactivation for IKur in the human atrial mathematical model (Courtemanche), adjusted according to data for inactivation in the pig atrium. (B) This plot shows the frequency dependence of IKur; this current is reduced in magnitude in response to pulses at higher frequencies. (C) Plot of the model action potential at 1 Hz under control conditions (to mimic the pig atrial action potential) and the plot of the action potential when IKur was completely blocked at 1 Hz.
Figure 5
Figure 5
Simulations of IKur block on rotor. (A) Left two panels depict representative snapshots of a rotor under control conditions, and when IKur was blocked completely, in carbachol-induced atrial fibrillation; right panels show respective dominant frequency maps. (B) Snapshot of spatial distribution of IKur and IK,ACh currents in a rotor during atrial fibrillation. (C) Top two left panels depict a dominant frequency map and a rotor snapshot when atrial fibrillation was induced in the absence of carbachol. The rotor tip trajectory before IKur block is plotted in blue. Bottom two left panels depict rotor snapshots in simulated atrial fibrillation (in the absence of IK,ACh) when IKur was blocked. The two snapshots are given at t = 3117 ms and just before termination of re-entry at t = 3177 ms. The rightmost panel depicts rotor tip meander before and after IKur block.
Figure 6
Figure 6
Effect of hyperkalaemia on simulated rotor. (A) The left panel depicts differences between the steady-state inactivation properties of INa in the atrium (red) and ventricle (blue). The inactivation is measured as the product of the fast (h) and the slow (j) sodium channel inactivation gates: hj. The right panel depicts how steady-state inactivation properties of INa vary as a function of increases in [K+]o. (B) The left panels show snapshots of the simulated rotor (with atrial model steady-state Na+ inactivation) at different values of [K+]o. The right panel depicts the trajectory of the rotor tip at different values of [K+]o. The rotor is seen to terminate at 6.2 mM [K+]o. (C) The top panel shows snapshots of the simulated rotor in a 3 × 3 cm tissue (with ventricular model steady-state Na+ inactivation) at different values of [K+]o. The rotor is seen to terminate at 10.6 mM [K+]o. The bottom panel depicts snapshots of the simulated rotor, but now in a 5 × 5 cm tissue (with ventricular INa) at different values of [K+]o. The rotor is now seen to terminate at 11.4 mM [K+]o.

References

    1. Nattel S. New ideas about atrial fibrillation 50 years on. Nature. 2002;415:219–226. doi:10.1038/415219a. - DOI - PubMed
    1. Page RL, Roden DM. Drug therapy for atrial fibrillation: where do we go from here? Nat Rev Drug Discov. 2005;4:899–910. doi:10.1038/nrd1876. - DOI - PubMed
    1. Ehrlich JR, Nattel S. Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope? Curr Opin Cardiol. 2009;24:50–55. doi:10.1097/HCO.0b013e32831bc336. - DOI - PubMed
    1. Gaborit N, Le Bouter S, Szuts V, Varro A, Escande D, Nattel S, et al. Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J Physiol. 2007;582:675–693. doi:10.1113/jphysiol.2006.126714. - DOI - PMC - PubMed
    1. Blaauw Y, Gögelein H, Tieleman RG, van Hunnik A, Schotten U, Allessie MA. Early' class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation. 2004;110:1717–1724. doi:10.1161/01.CIR.0000143050.22291.2E. - DOI - PubMed

Publication types